Latest Stents news
Ticagrelor, Prasugrel Compared in ACS Treated With PCI
posted July 6th
by modernClinician Editorial Team
by modernClinician Editorial Team
Deaths Not Up With Paclitaxel-Coated Devices in PAD
posted December 17th
by modernClinician Editorial Team
by modernClinician Editorial Team
Mortality Rate Not Up With Paclitaxel-Coated Devices in PAD
Black Race Linked to Increased MACE Risk After PCI
posted July 6th
by modernClinician Editorial Team
by modernClinician Editorial Team
FDA Investigating Paclitaxel-Coated Balloons, Paclitaxel-Eluting Stents
posted January 18th
by modernClinician Editorial Team
by modernClinician Editorial Team
The U.S. Food and Drug Administration alerted health care providers on Thursday that the agency is investigating the use of paclitaxel-coated balloons and paclitaxel-eluting stents to treat peripheral arterial disease in the femoropopliteal artery because of a potentially increased mortality risk in the long term.
Editor's Recommendations
Adverse Pregnancy Outcomes Linked to Increased Risk for Peripheral Artery Disease 
GLP-1 Receptor Agonists Linked to Lower Mortality, Amputation Rate in PAD and Type 2 Diabetes 
Risk for MACCE, Mortality Higher for Women With Severe CAD Undergoing PCI Versus CABG 
P2Y12 Inhibitor Monotherapy Beneficial for Patients Who Undergo PCI Related Articles
De-Escalating DAPT to Ticagrelor Monotherapy Cuts Bleeding Risk in Acute Coronary Syndrome 
In-Hospital Mortality Rare After Percutaneous Coronary Intervention 
No Increase in Long-Term Mortality Seen With Peripheral Drug-Coated Devices 
Patency of Iliac Vein Stents Examined in Subsequent Pregnancy Monthly Specialist Briefings
Stay Connected
